The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period. Corbus Pharmaceuticals Holdings's Dividend Payout Ratio for the
months ended in Mar. 2026 was 0.00.
The historical rank and industry rank for Corbus Pharmaceuticals Holdings's Dividend Payout Ratio or its related term are showing as below:
STU:3371's Dividend Payout Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 0.44 * Ranked among companies with meaningful Dividend Payout Ratio only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
Corbus Pharmaceuticals Holdings (STU:3371) Dividend Payout Ratio Explanation
In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Corbus Pharmaceuticals Holdings Dividend Payout Ratio Related Terms
Corbus Pharmaceuticals Holdings Dividend Payout Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corbus Pharmaceuticals Holdings Dividend Payout Ratio Chart
STU:3371 vs PRQR, NRXP, CRBU: Dividend Payout Ratio Comparison
For the Biotechnology subindustry, Corbus Pharmaceuticals Holdings's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corbus Pharmaceuticals Holdings Dividend Payout Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Corbus Pharmaceuticals Holdings's Dividend Payout Ratio distribution charts can be found below:
* The bar in red indicates where Corbus Pharmaceuticals Holdings's Dividend Payout Ratio falls into.
Corbus Pharmaceuticals Holdings Dividend Payout Ratio Calculation
The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corbus Pharmaceuticals Holdings (STU:3371) has a Dividend Payout Ratio of 0.00 as of Mar. 2026. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Corbus Pharmaceuticals Holdings and its competitors. According to the industry distribution chart, Corbus Pharmaceuticals Holdings ranks #999999 out of 133 companies in the Biotechnology industry.
Is Corbus Pharmaceuticals Holdings' Dividend Payout Ratio too high?
Corbus Pharmaceuticals Holdings' current Dividend Payout Ratio is 0.00. Based on the distribution chart, Corbus Pharmaceuticals Holdings ranks #999999 out of 133 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Corbus Pharmaceuticals Holdings has a GF Score™ of 31/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Corbus Pharmaceuticals Holdings' Dividend Payout Ratio compare to PRQR and NRXP?
According to the Biotechnology industry distribution chart, Corbus Pharmaceuticals Holdings ranks #999999 out of 133 companies for Dividend Payout Ratio. This places Corbus Pharmaceuticals Holdings in the lower half of its industry. The industry median Dividend Payout Ratio is 0.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Payout Ratio for a Biotechnology company?
The median Dividend Payout Ratio among Biotechnology companies is 0.44, based on 133 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Payout Ratio significantly above this median, while those in the bottom quartile fall well below. However, Dividend Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Payout Ratio mean?
A high Dividend Payout Ratio can signal that a stock is expensive relative to its fundamentals. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Corbus Pharmaceuticals Holdings and its competitors. For the Biotechnology industry, the median Dividend Payout Ratio is 0.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Corbus Pharmaceuticals Holdings's current Dividend Payout Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corbus Pharmaceuticals Holdings stock overvalued right now?
Based on GuruFocus' analysis, Corbus Pharmaceuticals Holdings (STU:3371) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.40, compared to a current price of €7.93 — trading 1881.3% above its estimated fair value. The current Dividend Payout Ratio is 0.00. Corbus Pharmaceuticals Holdings' overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Payout Ratio calculated?
Dividend Payout Ratio is calculated from a company's financial statements. For Corbus Pharmaceuticals Holdings (STU:3371), the current Dividend Payout Ratio is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Corbus Pharmaceuticals Holdings (STU:3371) Overvalued in 2026?
Based on GuruFocus' analysis, Corbus Pharmaceuticals Holdings stock appears to be overvalued.
The current stock price of €7.93 is trading 1881.3% above its estimated GF Value™ of €0.40.
GuruFocus considers Corbus Pharmaceuticals Holdings to be Significantly Overvalued.
Key valuation signals for STU:3371:
Dividend Payout Ratio: 0.00
GF Value™: €0.40 vs. price of €7.93 (1881.3% above fair value)
No single metric tells the full story. See the STU:3371 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Corbus Pharmaceuticals Holdings Business Description
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
31GF Score
Get the complete analysis for STU:3371
Dividend Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:3371 has been successfully added to your 
